PT Astrazeneca Indonesia (Indonesia)

Astrazeneca Indonesia is primarily engaged in pharmaceutical preparations activity. Its headquarters is located in Dki Jakarta. The company was founded in 1971. AstraZeneca Indonesia is a subsidiary of AstraZeneca PLC, a global biopharmaceutical company headquartered in Cambridge, United Kingdom. The company was established to cater to the growing healthcare needs in Indonesia, focusing on the research, development, and commercialization of prescription medicines. AstraZeneca's primary business lines include the development of innovative medicines in the areas of oncology, cardiovascular, renal & metabolism, and respiratory diseases. In Indonesia, AstraZeneca has expanded its presence with several branches and a robust distribution network to ensure the availability of its products across the country. The company is known for its leading products such as Tagrisso, Symbicort, and Crestor, which are well-regarded in the medical community. Globally, AstraZeneca operates in over 100 countries, with significant research and development facilities in Sweden, the United States, and China. The company collaborates with numerous healthcare organizations and research institutions to advance medical science and improve patient outcomes. AstraZeneca Indonesia is a member of various pharmaceutical and healthcare associations, contributing to the development of the industry in the region. The company is committed to sustainability and corporate responsibility, aligning with AstraZeneca's global mission to push the boundaries of science to deliver life-changing medicines. With a vision to transform the lives of patients, AstraZeneca Indonesia continues to invest in innovative healthcare solutions and aims to be a leader in the Indonesian pharmaceutical market.